文献速递MDS 与骨髓增殖性肿瘤

年龄作为核心疾病修饰因子:青少年和年轻成人原发性血小板增多症的临床、分子及预后特征

Age as a core disease modifier: Distinct clinical, molecular and prognostic landscapes of essential thrombocythaemia in adolescents and young adults.
PubMed 文献 · Br J Haematol · 2026-09-04

这项多中心回顾性研究纳入中国29个中心的1728例ET患者,分为AYA组(15-39岁,n=328)和非AYA组(≥40岁,n=1400)。AYA患者心血管风险更低、血栓发生率更低但极度血小板增多更常见,CALR突变富集而非驱动突变负荷更低,长期生存结局更优。AYA-ET是预后良好的独特临床分子亚型,支持年龄分层管理。

要点

  • AYA-ET患者心血管风险及血栓率更低,但极度血小板增多更常见。
  • AYA患者CALR突变富集,非驱动突变负荷更低,长期生存结局更优。
  • CALR突变在年轻患者中富集且与MF进展年龄特异性相关,提示靶向治疗需求。

核心结论

  • AYA-ET是预后良好的独特临床分子亚型,支持年龄分层管理。
  • 年轻患者CALR突变富集及其与MF进展的特异性关联提示需靶向CALR突变克隆的治疗。

研究设计与样本

  • 多中心回顾性研究,纳入中国29个中心的1728例ET患者。
  • 按年龄分层:AYA组(15-39岁,n=328)和非AYA组(≥40岁,n=1400)。
  • 比较临床特征、基因组 landscape、长期结局及post-ET MF进展危险因素。

主要发现

  • AYA患者心血管风险更低、血栓发生率更低,但极度血小板增多率更高。
  • AYA患者CALR突变富集,而JAK2突变在老年患者中占主导。
  • AYA患者非驱动突变(TET2、DNMT3A、ASXL1、SH2B3)负荷更低。
  • AYA患者总体生存、无骨髓纤维化生存及无白血病生存均更优。
  • CALR突变在年轻患者中富集,且与MF进展呈年龄特异性关联。

临床怎么用

  • 对AYA-ET患者应考虑年龄分层管理策略。
  • 年轻ET患者应关注CALR突变状态及其与MF进展的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Essential thrombocythaemia (ET) in adolescents and young adults (AYA, 15-39 years) is a distinct entity with an incompletely defined prognosis. In this multicentre retrospective study, 1728 ET patients from 29 centres across China were stratified into AYA (n = 328) and non-AYA (≥40 years, n = 1400) cohorts. We compared their clinical profiles, genomic landscapes, long-term outcomes and risk factors for progression to post-ET myelofibrosis (MF). AYA patients had fewer cardiovascular risks and lower thrombosis rates, but higher rates of extreme thrombocytosis. Molecularly, AYA patients were enriched for calreticulin (CALR) mutations, whereas Janus kinase 2 (JAK2) predominated in older patients. The burden of non-driver mutations (tet methylcytosine dioxygenase 2 [TET2], DNA methyltransferase 3A [DNMT3A], ASXL transcriptional regulator 1 [ASXL1], SH2‑B adaptor protein 3 [SH2B3]) was lower in AYA patients. Consequently, AYA patients achieved superior long-term outcomes across all key survival endpoints, including overall, myelofibrosis-free and leukaemia-free survival. Analysis of post-ET MF progression risks identified age-specific patterns: CALR mutations are enriched in younger patients and show an age-specific association with MF progression. AYA-ET constitutes a unique clinicomolecular subtype with a favourable prognosis, supporting age-stratified management. The enrichment of CALR mutations and their specific link to MF progression in young patients underscore the urgent need for targeted therapies against CALR-mutant clones.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Li J, Wen B, Yang X, et al. Age as a core disease modifier: Distinct clinical, molecular and prognostic landscapes of essential thrombocythaemia in adolescents and young adults. Br J Haematol. 2026. PMID: 42698068. doi:10.1111/bjh.70818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。